MedPath

XenoTherapeutics, Inc.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:1

Trial Phases

2 Phases

Phase 1:1
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (50.0%)
Phase 3
1 (50.0%)

Safety and Efficacy of realSKIN® to Provide Complete Wound Closure of Burn Wounds as an Alternative to Autografting

Phase 3
Recruiting
Conditions
Burn (Disorder)
Burn Degree Second
Burns Degree Third
Thermal Burn
Wound Heal
Interventions
Drug: Skin Xenotransplant
Procedure: Autograft(ing)
First Posted Date
2024-01-25
Last Posted Date
2025-04-02
Lead Sponsor
XenoTherapeutics, Inc.
Target Recruit Count
50
Registration Number
NCT06223269
Locations
🇺🇸

MaineHealth Maine Medical Center, Portland, Maine, United States

🇺🇸

Arizona Burn Center Valleywise Health, Phoenix, Arizona, United States

🇺🇸

JMS Burn Center at Doctors Hospital, Augusta, Georgia, United States

and more 1 locations

Evaluation of Safety and Efficacy of realSKIN® (Skin Xenotransplant) for Complete Closure of Severe Burn Wounds

Phase 1
Completed
Conditions
Deep Full-thickness Burn Injury (Disorder)
First Posted Date
2018-10-04
Last Posted Date
2024-01-12
Lead Sponsor
XenoTherapeutics, Inc.
Target Recruit Count
25
Registration Number
NCT03695939
Locations
🇺🇸

JMS Burn Center at Doctors Hospital, Augusta, Georgia, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

News

No news found
© Copyright 2025. All Rights Reserved by MedPath